By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics and genetic analysis products developer CapitalBio has received certification from China's State Food and Drug Administration for two microarray-based tests and for one amplification-based test for tuberculosis.

The two microarray assays can identify tuberculosis from spit samples, and they were developed for use with the company's LuxScan scanning and analysis tools, according to firm, which is based in Beijing.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.